Please login to the form below

Not currently logged in
Email:
Password:

Vectura to collaborate on COPD therapy

Respiratory disease specialist Vectura has said it is to collaborate with a 'leading pharmaceutical company' to develop and market new combination asthma/COPD therapy in the US

Respiratory disease specialist Vectura has said it is to collaborate with a 'leading pharmaceutical company' to develop and market a new combination asthma/COPD therapy in the US.

The unnamed company will replace Novartis' generics arm Sandoz in the deal to make use of Vectura's proprietary technology to bring investigational drug VR315 to the US market. Sandoz is continuing to develop for Europe.

Vectura will receive an initial payment of $10m, with $35m available in milestone payments. Royalties will also be available.

The company's partner will be responsible for the commercialisation and manufacture of the product together with clinical development.

Dr Chris Blackwell, CEO of Vectura, commented: "This is a major endorsement of the potential value of this product, Vectura's technology and product development expertise."

4th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics